MARKETS / NASDAQ / XAIR
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Beyond Air, Inc. XAIR

10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$7.7M
▲ 107.3% vs FY2024
EPS · FY25
$-4.01
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-337.4%
Net margin · FY25
-433.0%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 7.7M
Revenue, FY2025 · full 10-year series below
Revenue Net income
0.0020.0040.0060.0080.0-0.02016201920222025
0.0020.0040.0060.0080.0-0.02016201920222025

The company lost 433 cents on every revenue dollar this year.

Per share
USD -4.01
Diluted EPS, FY2025
EPS
0.40.81.2-4.012016201920222025
0.40.81.2-4.012016201920222025

The company pays no cash dividend.

Profitability
-337.4%
Return on equity, FY2025
ROE
0.250.50.751-337.4%2016201920222025
0.250.50.751-337.4%2016201920222025
Operating margin-378.2%
Net margin-433.0%
Return on assets-101.6%

Each USD of equity lost 337 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+54.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+54.5%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.01B
Shares outstanding, FY2025
0.000.012016201920222025
0.000.012016201920222025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 35.4M
total assets, end of FY2025
Total assetsUSD 35.4M
EquityUSD 6.1M
CashUSD 6.7M
Current ratio3.80×

Equity funds 17% of total assets.

History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
0.0
0.0
0.0
·
·
0.0
0.0
0.0
·
·
Operating income $B
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
·
·
·
·
−0.0
·
·
0.0
Net income $B
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−4.01
−13.77
−1.82
−1.86
·
−1.27
−1.78
−0.77
−3.01
−2.69
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
−337.4
−241.4
−191.4
−100.9
−83.7
−94.2
−180.3
−235.5
·
·
Shares out B
0.01
0.00
0.05
0.03
0.03
0.02
0.02
0.01
0.01
0.00

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
33 of 33
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed